Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Get Free Report) CEO Ian Mortimer sold 10,830 shares of the business's stock in a transaction dated Monday, December 8th. The stock was sold at an average price of $45.73, for a total transaction of $495,255.90. Following the completion of the sale, the chief executive officer owned 6,000 shares in the company, valued at approximately $274,380. This trade represents a 64.35% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.
Ian Mortimer also recently made the following trade(s):
- On Friday, December 5th, Ian Mortimer sold 14,375 shares of Xenon Pharmaceuticals stock. The shares were sold at an average price of $45.03, for a total transaction of $647,306.25.
- On Friday, November 28th, Ian Mortimer sold 97 shares of Xenon Pharmaceuticals stock. The stock was sold at an average price of $45.01, for a total value of $4,365.97.
- On Wednesday, October 1st, Ian Mortimer sold 25,000 shares of Xenon Pharmaceuticals stock. The shares were sold at an average price of $40.16, for a total value of $1,004,000.00.
Xenon Pharmaceuticals Price Performance
NASDAQ:XENE opened at $43.52 on Wednesday. The firm has a market capitalization of $3.36 billion, a price-to-earnings ratio of -11.19 and a beta of 1.03. The business has a 50 day simple moving average of $41.41 and a 200-day simple moving average of $36.70. Xenon Pharmaceuticals Inc. has a 1 year low of $26.74 and a 1 year high of $46.60.
Xenon Pharmaceuticals (NASDAQ:XENE - Get Free Report) last released its quarterly earnings results on Monday, November 3rd. The biopharmaceutical company reported ($1.15) earnings per share for the quarter, beating the consensus estimate of ($1.16) by $0.01. The business's quarterly revenue was up .0% on a year-over-year basis. During the same period in the previous year, the business posted ($0.81) EPS. As a group, analysts expect that Xenon Pharmaceuticals Inc. will post -3.1 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Xenon Pharmaceuticals
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Holocene Advisors LP purchased a new stake in Xenon Pharmaceuticals in the 2nd quarter valued at about $56,637,000. Wellington Management Group LLP raised its stake in shares of Xenon Pharmaceuticals by 66.0% during the third quarter. Wellington Management Group LLP now owns 3,609,857 shares of the biopharmaceutical company's stock valued at $144,936,000 after acquiring an additional 1,435,096 shares in the last quarter. Geode Capital Management LLC boosted its holdings in shares of Xenon Pharmaceuticals by 1,294.2% in the second quarter. Geode Capital Management LLC now owns 970,343 shares of the biopharmaceutical company's stock valued at $30,369,000 after purchasing an additional 900,746 shares during the period. Braidwell LP boosted its holdings in shares of Xenon Pharmaceuticals by 33.0% in the second quarter. Braidwell LP now owns 3,605,029 shares of the biopharmaceutical company's stock valued at $112,837,000 after purchasing an additional 895,154 shares during the period. Finally, Vestal Point Capital LP grew its stake in Xenon Pharmaceuticals by 53.8% in the second quarter. Vestal Point Capital LP now owns 2,000,000 shares of the biopharmaceutical company's stock worth $62,600,000 after purchasing an additional 700,000 shares in the last quarter. Institutional investors own 95.45% of the company's stock.
Analysts Set New Price Targets
XENE has been the topic of several recent analyst reports. Wells Fargo & Company reissued an "overweight" rating and issued a $44.00 target price (down previously from $48.00) on shares of Xenon Pharmaceuticals in a research note on Tuesday, November 4th. Royal Bank Of Canada lifted their price target on shares of Xenon Pharmaceuticals from $55.00 to $58.00 and gave the stock an "outperform" rating in a research note on Tuesday, November 4th. Chardan Capital raised shares of Xenon Pharmaceuticals to a "strong-buy" rating in a research report on Wednesday, November 19th. Bloom Burton raised shares of Xenon Pharmaceuticals to a "strong-buy" rating in a research note on Tuesday, October 7th. Finally, JPMorgan Chase & Co. boosted their target price on Xenon Pharmaceuticals from $57.00 to $60.00 and gave the company an "overweight" rating in a research report on Tuesday, November 18th. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, Xenon Pharmaceuticals presently has an average rating of "Buy" and an average price target of $54.27.
Get Our Latest Stock Report on Xenon Pharmaceuticals
About Xenon Pharmaceuticals
(
Get Free Report)
Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
